

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Tryptamine Therapeutics Limited
ABN	41 671 790 935

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Jason Carroll
Date of last notice	6 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Direct (3) Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	(1) 6 June 2024
No. of securities held prior to change	(1) 34,452,748 - ORDINARY FULLY PAID SHARES (2) 20,000,000 - TRYP TRANS OPT @ \$0.027 EXP 3 YEARS REINSTATEMENT 24M ESC (3) 27,892,190 - EMPOPT F @ \$0.0338 EXP 30/10/28 24M ESC
Class	(1) ORDINARY FULLY PAID SHARES (2) TRYP TRANS OPT @ \$0.027 EXP 3 YEARS REINSTATEMENT 24M ESC (3) EMPOPT F @ \$0.0338 EXP 30/10/28 24M ESC
Number acquired	(1) 1,692,514 - ORDINARY FULLY PAID SHARES
Number disposed	N/A
Value/Consideration	(1) \$0.02132 PER ORDINARY FULLY PAID SHARES (IN TOTAL \$36,090.04)

⁺ See [chapter 19](#) for defined terms.

No. of securities held after change	(1) 36,145,262 - ORDINARY FULLY PAID SHARES (2) 20,000,000 - TRYP TRANS OPT @ \$0.027 EXP 3 YEARS REINSTATEMENT 24M ESC (3) 27,892,190 - EMPOPT F @ \$0.0338 EXP 30/10/28 24M ESC
Nature of change	(1) ON-MARKET ACQUISITION

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.